• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

代谢综合征与子宫内膜癌患者生存率的关系：一项荟萃分析。

The relationship between metabolic syndrome and survival of patients with endometrial cancer: a meta-analysis.

作者信息

Deng Feng, Chen Yi, Wu Ying, Tang Yawen, Yi Wangjun

机构信息

Department of Gynecology, The Third Hospital of Changsha, Changsha, Hunan, China.

出版信息

Front Oncol. 2024 Oct 21;14:1484109. doi: 10.3389/fonc.2024.1484109. eCollection 2024.

DOI:10.3389/fonc.2024.1484109
PMID:39497714
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11532107/
Abstract

BACKGROUND

Metabolic syndrome (MetS) is associated with a high risk of endometrial cancer (EC). However, its impact on EC progression remains unclear. This meta-analysis examined the association between MetS and survival outcomes in EC patients.

METHODS

A comprehensive search of PubMed, EMBASE, and Web of Science databases up to May 22, 2024, was conducted. Two independent reviewers performed study selection, data extraction, and quality assessment. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using a random effects model.

RESULTS

Nine studies comprising 13,579 endometrial cancer (EC) patients were included. Among these, 2,896 patients (21.3%) had MetS at the time of enrollment. The follow-up durations ranged from 3.4 to 14.2 years. The results showed that EC patients with MetS at baseline demonstrated significantly poorer overall survival (HR = 1.57, 95% CI = 1.19-2.07, = 0.002; I = 25%) and progression-free survival (HR = 1.33, 95% CI = 1.08-1.63, = 0.007; I = 16%). A similar association was observed for cancer-specific survival (HR = 1.26, 95% CI = 1.10-1.44, = 0.001; I = 0%). Subgroup analyses based on study characteristics showed consistent results across studies conducted in countries with different follow-up durations.

CONCLUSION

This meta-analysis suggests that MetS is associated with poor survival outcomes in EC patients. Further prospective studies are required to validate our findings.

SYSTEMATIC REVIEW REGISTRATION

PROSPERO, identifier CRD42024561654.

摘要

背景

代谢综合征（MetS）与子宫内膜癌（EC）的高风险相关。然而，其对EC进展的影响仍不清楚。本荟萃分析探讨了MetS与EC患者生存结局之间的关联。

方法

对截至2024年5月22日的PubMed、EMBASE和Web of Science数据库进行全面检索。两名独立的评审员进行研究筛选、数据提取和质量评估。使用随机效应模型计算风险比（HRs）和95%置信区间（CIs）。

结果

纳入了9项研究，共13579例子宫内膜癌（EC）患者。其中，2896例患者（21.3%）在入组时患有MetS。随访时间为3.4至14.2年。结果显示，基线时患有MetS的EC患者总体生存率显著较差（HR = 1.57，95% CI = 1.19 - 2.07，P = 0.002；I² = 25%），无进展生存率也较差（HR = 1.33，95% CI = 1.08 - 1.63，P = 0.007；I² = 16%）。在癌症特异性生存方面也观察到类似的关联（HR = 1.26，95% CI = 1.10 - 1.44，P = 0.001；I² = 0%）。基于研究特征的亚组分析显示，在不同随访时间的国家进行的研究结果一致。

结论

本荟萃分析表明，MetS与EC患者的不良生存结局相关。需要进一步的前瞻性研究来验证我们的发现。

系统评价注册

PROSPERO，标识符CRD42024561654。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25af/11532107/4c0047220e24/fonc-14-1484109-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25af/11532107/3a44c4ac945c/fonc-14-1484109-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25af/11532107/b9e01fa966fe/fonc-14-1484109-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25af/11532107/fd16e75c0b9c/fonc-14-1484109-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25af/11532107/d39fe29ab655/fonc-14-1484109-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25af/11532107/696ef776fb47/fonc-14-1484109-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25af/11532107/edad9f0c41f7/fonc-14-1484109-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25af/11532107/4c0047220e24/fonc-14-1484109-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25af/11532107/3a44c4ac945c/fonc-14-1484109-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25af/11532107/b9e01fa966fe/fonc-14-1484109-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25af/11532107/fd16e75c0b9c/fonc-14-1484109-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25af/11532107/d39fe29ab655/fonc-14-1484109-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25af/11532107/696ef776fb47/fonc-14-1484109-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25af/11532107/edad9f0c41f7/fonc-14-1484109-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25af/11532107/4c0047220e24/fonc-14-1484109-g007.jpg

相似文献

1
The relationship between metabolic syndrome and survival of patients with endometrial cancer: a meta-analysis.代谢综合征与子宫内膜癌患者生存率的关系：一项荟萃分析。
Front Oncol. 2024 Oct 21;14:1484109. doi: 10.3389/fonc.2024.1484109. eCollection 2024.
2
Prognostic Nutritional Index and the Survival of Patients with Endometrial cancer: A Meta-analysis.预后营养指数与子宫内膜癌患者的生存：一项Meta分析
Reprod Sci. 2024 Dec;31(12):3779-3794. doi: 10.1007/s43032-024-01686-6. Epub 2024 Sep 23.
3
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区，服用抗叶酸抗疟药物的人群中，叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
4
Association between metabolic syndrome and endometrial cancer risk: a systematic review and meta-analysis of observational studies.代谢综合征与子宫内膜癌风险的关联：观察性研究的系统评价和荟萃分析。
Aging (Albany NY). 2020 May 22;12(10):9825-9839. doi: 10.18632/aging.103247.
5
Survival outcomes in endometrial cancer patients according to diabetes: a systematic review and meta-analysis.根据糖尿病对子宫内膜癌患者生存结局的影响：系统评价和荟萃分析。
BMC Cancer. 2022 Apr 20;22(1):427. doi: 10.1186/s12885-022-09510-7.
6
Prognostic and Clinicopathological Role of PD-L1 in Endometrial Cancer: A Meta-Analysis.PD-L1在子宫内膜癌中的预后及临床病理作用：一项Meta分析
Front Oncol. 2020 Apr 30;10:632. doi: 10.3389/fonc.2020.00632. eCollection 2020.
7
Influence of metabolic syndrome on prognosis of patients with surgically treated esophageal cancer: a meta-analysis.代谢综合征对手术治疗食管癌患者预后的影响：一项荟萃分析。
Diabetol Metab Syndr. 2024 May 23;16(1):111. doi: 10.1186/s13098-024-01335-7.
8
Prognostic value of inflammatory markers NLR, PLR, and LMR in gastric cancer patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review.免疫检查点抑制剂治疗胃癌患者中炎症标志物 NLR、PLR 和 LMR 的预后价值：荟萃分析和系统评价。
Front Immunol. 2024 Jul 10;15:1408700. doi: 10.3389/fimmu.2024.1408700. eCollection 2024.
9
Prognosis of polymerase epsilon (POLE) mutation in high-grade endometrioid endometrial cancer: Systematic review and meta-analysis.POLE 基因突变在高级别子宫内膜样腺癌中的预后：系统评价和荟萃分析。
Gynecol Oncol. 2024 Mar;182:99-107. doi: 10.1016/j.ygyno.2024.01.018. Epub 2024 Jan 22.
10
Associations of metformin therapy treatment with endometrial cancer risk and prognosis: A systematic review and meta-analysis.二甲双胍治疗与子宫内膜癌风险和预后的相关性：系统评价和荟萃分析。
Gynecol Oncol. 2024 Mar;182:15-23. doi: 10.1016/j.ygyno.2024.01.007. Epub 2024 Jan 20.

引用本文的文献

1
LncRNA MALAT1 as a prognostic biomarker in endometrial cancer: a molecular genetics approach.长链非编码RNA MALAT1作为子宫内膜癌的预后生物标志物：一种分子遗传学方法。
Discov Oncol. 2025 Jul 1;16(1):1231. doi: 10.1007/s12672-025-02748-0.

本文引用的文献

1
Metabolic Syndrome and Survival Outcomes in Endometrial Cancer.子宫内膜癌中的代谢综合征与生存结局
Cureus. 2024 May 15;16(5):e60324. doi: 10.7759/cureus.60324. eCollection 2024 May.
2
Prognostic impact of metabolic syndrome in patients with primary endometrial cancer: a retrospective bicentric study.代谢综合征对原发性子宫内膜癌患者预后的影响：一项回顾性的两中心研究。
J Cancer Res Clin Oncol. 2024 Apr 3;150(4):174. doi: 10.1007/s00432-024-05699-1.
3
Cancer statistics, 2024.2024年癌症统计数据。
CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. doi: 10.3322/caac.21820. Epub 2024 Jan 17.
4
Global and regional trends in the incidence and mortality burden of endometrial cancer, 1990-2019: Updated results from the Global Burden of Disease Study, 2019.1990 - 2019年子宫内膜癌发病率和死亡率负担的全球及区域趋势：2019年全球疾病负担研究的更新结果
Chin Med J (Engl). 2024 Feb 5;137(3):294-302. doi: 10.1097/CM9.0000000000002841. Epub 2023 Oct 24.
5
Metabolic risk score as a predictor in a nomogram for assessing myometrial invasion for endometrial cancer.代谢风险评分作为预测子宫内膜癌肌层浸润的列线图中的一个预测指标。
Oncol Lett. 2023 Feb 6;25(3):114. doi: 10.3892/ol.2023.13700. eCollection 2023 Mar.
6
Management of Patients Diagnosed with Endometrial Cancer: Comparison of Guidelines.子宫内膜癌确诊患者的管理：指南比较
Cancers (Basel). 2023 Feb 8;15(4):1091. doi: 10.3390/cancers15041091.
7
Role of adipocytokines in endometrial cancer progression.脂肪细胞因子在子宫内膜癌进展中的作用。
Front Pharmacol. 2022 Dec 12;13:1090227. doi: 10.3389/fphar.2022.1090227. eCollection 2022.
8
Advanced and recurrent endometrial cancer: State of the art and future perspectives.高级别和复发性子宫内膜癌：现状和未来展望。
Crit Rev Oncol Hematol. 2022 Dec;180:103851. doi: 10.1016/j.critrevonc.2022.103851. Epub 2022 Oct 17.
9
Association between subtypes of metabolic syndrome and prognosis in patients with stage I endometrioid adenocarcinoma: A retrospective cohort study.代谢综合征亚型与Ⅰ期子宫内膜样腺癌患者预后的关联：一项回顾性队列研究。
Front Oncol. 2022 Sep 20;12:950589. doi: 10.3389/fonc.2022.950589. eCollection 2022.
10
Metabolic syndrome, obesity and cancer risk.代谢综合征、肥胖与癌症风险。
Curr Opin Urol. 2022 Nov 1;32(6):594-597. doi: 10.1097/MOU.0000000000001041. Epub 2022 Sep 8.